Figure 4. IL-1β and IL-23 promotes growth of 4T1 tumor. BALB/c mice (n=6) were injected with 4T1 cells as described. From day 3 post cell inoculation, mice were injected with rmIL-1β (20 μg/kg) and/or rmIL-23 (20 μg/kg) with or without anti-murine IL-22 (5 mg/kg) thrice weekly for 3 weeks. (A) Tumor size was measured continuously. On day 24, tumors were collected for morphological (B) and histological analyses (C). Histological analyses were performed by H&E staining and Ki-67 immunohistochemical staining. Scale bar: 500 μm. (D) Percent of Ki-67-positive cells were counted (n=4). Data are from two independent experiments. Data are mean ± SD, compared using one-way ANOVA test. *p < 0.05.